Table 3. Screened Drugs Chlorthalidone, Droperidol, Darifenacin, Adinozolam, and Mazindol Association with Predicted Genes.
| genes | interaction scores | functions/diseases | references | |
|---|---|---|---|---|
| chlorthalidone | NPPA | 5.68 | osteoarthritis, spine | (39) |
| SLC12A1 | 3.03 | osteosarcoma | (40) | |
| AGT | 0.33 | childhood osteosarcoma | (41) | |
| SLC12A3 | 0.32 | sarcoma, neoplasms | (42) | |
| CA1 | 0.44 | neoplasms | (43) | |
| CA14 | 0.41 | malignant neoplasms | (44) | |
| CA7 | 0.36 | colorectal carcinoma | (45) | |
| ACE | 0.16 | synovial sarcoma | (46) | |
| CA4 | 0.25 | retinitis pigmentosa 17 | (47) | |
| MMP3 | 0.21 | osteosarcoma of bone; primary osteosarcoma | (48, 49) | |
| droperidol | DRD2 | 0.35 | malignant bone neoplasm; osteosarcoma of bone | (36) |
| KCNH2 | 0.04 | malignant neoplasm of prostate | (50) | |
| DRD4 | 0.11 | carcinoma of the lung | (51) | |
| ADRA1A | 0.09 | osteoporosis | (52) | |
| DRD3 | 0.08 | neoplasms | (53) | |
| CYP2D6 | 0.01 | bone cysts, aneurysmal | (54) | |
| HTR2A | 0.04 | osteosarcoma of bone; childhood osteosarcoma | (37) | |
| darifenacin | CHRM3 | 0.61 | osteosarcoma of bone | (37) |
| CHRM1/2 | 0.32 | mental depression | (55) | |
| CHRM4 | 0.46 | schizophrenia | (56) | |
| CHRM5 | 0.45 | systemic scleroderma | (57) | |
| CYP2D6 | 0.03 | eosinophilia-myalgia syndrome | (58) | |
| adinozolam | GABRR3/2 | 0.46 | restless legs syndrome | (59) |
| GABRR1 | 0.43 | migraine disorders | (60) | |
| GABRP | 0.22 | tumor progression | (61) | |
| GABRE | 0.22 | malignant neoplasms | (62) | |
| GABRD | 0.21 | Rett syndrome | (63) | |
| GABRG1 | 0.21 | body height | (64) | |
| mazindol | SLC6A3 | 1.27 | scoliosis | (65) |
| SLC6A2 | 0.97 | childhood osteosarcoma; osteosarcoma of bone | (66) | |
| SLC18A2 | 0.56 | childhood osteosarcoma; osteosarcoma of bone | (66) | |
| SLC6A4 | 0.21 | synovial sarcoma | (67) | |
| NAT1 | 0.16 | neoplasms | (68) | |
| HTT | 0.05 | Huntington Disease | (69) |